Rare Brain Tumor That Vanishes on Its Own Seen Before Birth in Striking Case Report

In the shadowy world of pediatric vascular tumors, one of the rarest and most puzzling entities has just been documented in extraordinary detail. Radiologists and clinicians at the University of North Carolina at Chapel Hill, working with a colleague from Pontifícia Universidade Católica do Paraná in Brazil, have reported a case of a rapidly involuting congenital hemangioma — a RICH — arising in the suprasellar region of a fetal brain, an anatomical location where this tumor has almost never been described. The case, published in the journal Pediatric Radiology, is notable not only for its rarity but for the completeness of its imaging record: the lesion was captured on prenatal ultrasound and fetal magnetic resonance imaging, then tracked with postnatal ultrasound and MRI as it shrank with remarkable speed. For a tumor sitting perilously close to the pituitary gland, the optic pathways, and the hypothalamus, that spontaneous retreat is nothing short of astonishing.

To understand why this case matters, it helps to know how vascular tumors of infancy are classified. Hemangiomas are the most common vascular tumors of infancy, and clinicians broadly divide them into infantile hemangiomas, which typically appear after birth and grow during early infancy, and congenital hemangiomas, which are fully formed by the time a baby is born. Congenital hemangiomas are themselves split into three behavioral categories: rapidly involuting congenital hemangiomas, which regress quickly after birth; non-involuting congenital hemangiomas, which persist indefinitely; and partially involuting congenital hemangiomas, which shrink somewhat but never disappear entirely. This three-way classification, formalized in influential work by Mulliken and Enjolras, reflects the fact that these tumors behave in fundamentally different ways despite looking superficially similar under the microscope.

The genetic underpinnings of congenital hemangiomas have become clearer in the past decade. Researchers have identified somatic activating mutations in the GNAQ and GNA11 genes in these tumors — alterations that occur in the tumor tissue itself rather than being inherited, and that drive the abnormal proliferation of blood vessel cells. This molecular signature distinguishes congenital hemangiomas from infantile hemangiomas, which follow a different biological program altogether. One of the classic diagnostic markers separating the two is GLUT1, a glucose transporter protein that is abundantly expressed in infantile hemangiomas but characteristically absent in congenital ones. Immunohistochemical staining for GLUT1, first described as a diagnostic marker for juvenile hemangiomas in landmark work published in 2000, remains a cornerstone of daily practice in distinguishing cutaneous vascular anomalies.

Most congenital hemangiomas appear on the skin and soft tissues of the head and neck or around the joints of the extremities — the periarticular regions. A RICH on a scalp or a knee is unusual enough; a RICH inside the brain, in the suprasellar region, is a genuine medical rarity. The suprasellar region is one of the most crowded and consequential addresses in the human brain. It houses the pituitary gland, the optic chiasm, the hypothalamus, and the circle of Willis, the arterial ring that supplies blood to much of the cerebrum. Tumors in this location — whether congenital craniopharyngiomas, hypothalamic hamartomas, or other lesions — can threaten vision, hormone regulation, and core metabolic functions, and they often demand delicate neurosurgical intervention. The prospect of a vascular tumor growing there before birth is the kind of finding that sets off immediate alarm bells in any fetal imaging suite.

That is precisely what makes the new report so valuable. The lesion was first detected on prenatal ultrasound, the workhorse of fetal surveillance, and then further characterized with fetal MRI, which offers superior soft-tissue contrast and can help differentiate vascular lesions from other fetal brain tumors. Fetal brain tumors themselves are exceedingly rare, and imaging them well is a technical challenge; a dedicated review of fetal brain tumor imaging published in Pediatric Radiology in 2020 underscored how difficult it can be to pin down a precise prenatal diagnosis. In this case, the imaging features and clinical course pointed toward a RICH, and the diagnosis was confirmed by the tumor’s behavior after birth: serial postnatal ultrasound and MRI demonstrated rapid interval regression, the hallmark of the rapidly involuting subtype.

The natural history of RICH tumors is what gives this case its happy ending. These tumors are fully grown at birth — they do not exhibit the postnatal proliferation phase that defines infantile hemangiomas — and then they begin to shrink, often dramatically, during the first months of life. Many resolve completely, sometimes leaving behind only a subtle patch of atrophic skin or residual telangiectasias when they occur on the skin. The speed of involution can be striking, which is how the subtype earned its name. But the behavior of a RICH in the brain is far less well charted than its cutaneous counterpart, simply because so few intracranial cases have been reported. Prior reports have described RICH lesions of the skull and the hand, and one team documented prenatal diagnosis and postnatal follow-up of a RICH in this same journal more than a decade ago, but suprasellar examples remain vanishingly scarce.

The clinical stakes of such a diagnosis are considerable. Congenital hemangiomas are usually benign and self-limited, but they are not always harmless. Rare catastrophic cases have been described in which congenital hemangiomas caused severe coagulopathy — a consumption of clotting factors by the tumor’s high-flow vasculature — leading to fatal cardiac failure in newborns. High-flow vascular lesions in the brain carry additional risks, including hemorrhage and mass effect on critical structures. For families and clinicians facing a prenatal diagnosis of a suprasellar mass, the differential diagnosis includes lesions with far grimmer prognoses, and the temptation toward aggressive intervention can be strong. A documented case in which watchful waiting was rewarded by spontaneous, imaging-confirmed regression provides a crucial data point: not every prenatal brain mass is a surgical emergency, and accurate diagnosis can spare an infant invasive procedures.

That said, the report also implicitly acknowledges that not all congenital hemangiomas can be left alone. When these tumors cause serious complications, medical therapy has entered the picture in recent years. Sirolimus, an mTOR inhibitor better known as an immunosuppressant, has emerged as a treatment option for problematic vascular anomalies, and a 2026 report in Pediatric Blood & Cancer described the successful management of a refractory congenital hemangioma with sirolimus in a neonate. The decision matrix for a neonatal vascular tumor thus spans a spectrum from simple observation to pharmacotherapy to, in select cases, surgery — and the choice hinges on accurate subtype classification, which is exactly where detailed imaging documentation like that in this new case report earns its keep.

For the radiology community, the case adds a rare entry to the atlas of fetal and neonatal intracranial vascular tumors, complete with the kind of longitudinal imaging follow-up that textbooks crave. For the broader public, it is a reminder of how much the prenatal imaging revolution has changed medicine: a tumor invisible to any previous generation of doctors is now spotted on ultrasound before a baby takes its first breath, characterized by MRI in utero, and tracked noninvasively as it resolves. The researchers reported no competing interests, obtained written informed consent from the child’s parents, and noted that institutional review board approval was not required for this single case report under institutional policies. The authors — Noman Khan, Rafaela Minguetti, Alexandra J. Borst, Kimberly M. Hamilton, and Carolina V. Guimaraes — frame the contribution around the clinical course and imaging features of the lesion, offering colleagues worldwide a template for recognizing a diagnosis that most will encounter only once, if ever, in their careers.

Behind the technical narrative lies a genuinely moving human story: parents who learned before birth that their child had a mass in one of the most delicate regions of the brain, and who then watched, scan by scan, as that mass melted away on its own. Medicine’s growing ability to distinguish tumors that threaten from tumors that retreat — using imaging signatures, immunohistochemical markers like GLUT1, and now somatic genetics — is quietly transforming outcomes for infants like this one. In an era when the word tumor triggers instinctive dread, this suprasellar RICH stands as a counterexample: a lesion that arrived fully formed, announced itself on fetal MRI, and then, true to its name, vanished in a rush — leaving behind only images, data, and a rare lesson in the power of knowing when to do nothing at all.

Subject of Research: A rare case of rapidly involuting congenital hemangioma in the fetal suprasellar brain region documented by prenatal and postnatal imaging

Article Title: Rapidly involuting congenital hemangioma of the suprasellar region

Article References: Khan, N., Minguetti, R., Borst, A. J., Hamilton, K. M., & Guimaraes, C. V. (2026). Rapidly involuting congenital hemangioma of the suprasellar region. Pediatric Radiology. https://doi.org/10.1007/s00247-026-06780-2

Image Credits: AI Generated

DOI: 10.1007/s00247-026-06780-2

Keywords: congenital hemangioma, RICH, suprasellar region, fetal MRI, prenatal diagnosis, pediatric radiology, vascular tumors, GLUT1, GNAQ mutation, infantile hemangioma, spontaneous regression, neonatal imaging